Skip to main content
. 2017 Sep 11;20(1):97–104. doi: 10.1007/s40272-017-0264-y
This is the first study of palivizumab use in children with immunocompromised conditions or Down syndrome conducted in a real-world setting.
Palivizumab was well tolerated and effective in preventing hospitalization due to severe RSV infection.